AU719841B2 - Novel human metabotropic glutamate receptor - Google Patents

Novel human metabotropic glutamate receptor Download PDF

Info

Publication number
AU719841B2
AU719841B2 AU37156/97A AU3715697A AU719841B2 AU 719841 B2 AU719841 B2 AU 719841B2 AU 37156/97 A AU37156/97 A AU 37156/97A AU 3715697 A AU3715697 A AU 3715697A AU 719841 B2 AU719841 B2 AU 719841B2
Authority
AU
Australia
Prior art keywords
metabotropic glutamate
nucleic acid
amino acid
glutamate receptor
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU37156/97A
Other languages
English (en)
Other versions
AU3715697A (en
Inventor
Forrest H. Fuller
Lance G. Hammerland
Rachel T. Simin
Thomas M Stormann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NPS Pharmaceuticals Inc filed Critical NPS Pharmaceuticals Inc
Publication of AU3715697A publication Critical patent/AU3715697A/en
Application granted granted Critical
Publication of AU719841B2 publication Critical patent/AU719841B2/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Alteration of Name(s) in Register under S187 Assignors: NPS PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU37156/97A 1996-02-21 1997-02-20 Novel human metabotropic glutamate receptor Ceased AU719841B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/604,298 US6084084A (en) 1996-02-21 1996-02-21 Human metabotropic glutamate receptor
US08/604298 1996-02-21
PCT/US1997/009025 WO1997048724A2 (en) 1996-02-21 1997-02-20 Human metabotropic glutamate receptor

Publications (2)

Publication Number Publication Date
AU3715697A AU3715697A (en) 1998-01-07
AU719841B2 true AU719841B2 (en) 2000-05-18

Family

ID=24419059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37156/97A Ceased AU719841B2 (en) 1996-02-21 1997-02-20 Novel human metabotropic glutamate receptor

Country Status (10)

Country Link
US (3) US6084084A (enExample)
EP (1) EP0882065B1 (enExample)
JP (1) JP2000506392A (enExample)
AT (1) ATE369385T1 (enExample)
AU (1) AU719841B2 (enExample)
CA (1) CA2246751A1 (enExample)
DE (1) DE69737990T2 (enExample)
ES (1) ES2292193T3 (enExample)
IL (2) IL125711A0 (enExample)
WO (1) WO1997048724A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
JPH10507934A (ja) * 1995-07-26 1998-08-04 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 代謝指向型グルタミン酸受容体に活性を示す化合物を同定するためのキメラ受容体および方法、ならびに神経学的障害および疾患の治療におけるそのような化合物の使用
US6221609B1 (en) * 1996-07-03 2001-04-24 Eli Lilly And Company Isolate nucleic acid encoding human MGLUR8
CA2325334A1 (en) * 1998-04-03 1999-10-14 Nps Pharmaceuticals, Inc. G-protein fusion receptors and chimeric gabab receptors
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
EP1662255A3 (en) * 1998-08-18 2006-09-13 The Johns Hopkins University School Of Medicine Homer interacting proteins
EP1105734A4 (en) * 1998-08-18 2005-04-13 Univ Johns Hopkins Med PROTEINS WITH INTERACTION OF THE HOMER FAMILY
BR9913311A (pt) * 1998-08-31 2001-10-16 Trinity College Dublin Molécula de ácido nucleico isolado, ácido nucleico isolado, vetor, proteìna, anticorpo e anti-soros formados contra uma proteìna, kit de diagnóstico, processos para reduzir a infecção de estafilococos coagulase-negativos de um dispositivo médico de retenção, para tratar uma infecção de estafilococus coagulase-negativa, para prevenir uma infecção de estafilococos coagulase-negativa em um paciente, para induzir uma resposta imunológica e para identificar compostos que inibem estafilococos coagulase-negativos
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US6620850B2 (en) * 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
WO2003054167A2 (en) * 2001-12-20 2003-07-03 Merck & Co., Inc. Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
WO2003059291A2 (en) * 2002-01-10 2003-07-24 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
WO2004050858A2 (en) * 2002-12-04 2004-06-17 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
US20050186658A1 (en) * 2003-10-17 2005-08-25 Nps Pharmaceuticals, Inc. Chimeric metabotropic glutamate receptors and uses thereof
WO2005073730A1 (en) * 2004-01-31 2005-08-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human metabotropic glutamate receptor 8 (mglur8)
WO2006044611A2 (en) * 2004-10-14 2006-04-27 Carnegie Institution Of Washington Neurotransmitter sensors and methods of using the same
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
US8889950B2 (en) * 2006-07-28 2014-11-18 The George Washington University Repression of AtGLR3.2 increases plant biomass
US7424876B2 (en) * 2006-10-06 2008-09-16 Ford Global Technologies, Llc Pushrod engine with multiple independent lash adjusters for each pushrod
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CA2696948C (en) 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
WO2009079566A2 (en) * 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
EP2315833B8 (en) 2008-05-20 2015-05-27 Eos Neuroscience, Inc. Vectors for delivery of light-sensitive proteins and methods of use
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
BRPI0921333A2 (pt) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
KR20250008141A (ko) 2015-08-07 2025-01-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1311829A (en) * 1971-02-20 1973-03-28 Hayashibara Co Sealsoning of comestibles
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5177011A (en) * 1988-08-18 1993-01-05 Calgene, Inc. Plant elongation factor promoters, coding sequences and uses
JP2944721B2 (ja) * 1990-08-22 1999-09-06 生化学工業株式会社 エンドトキシンの測定剤
NZ240921A (en) * 1990-12-12 1994-06-27 Zymogenetics Inc G protein coupled glutamate receptor (neurotransmitters), recombinant production
DK0724561T3 (da) * 1991-08-23 2004-06-28 Nps Pharma Inc Calciumreceptoraktive arylalkylaminer
ES2256370T3 (es) * 1991-08-23 2006-07-16 Nps Pharmaceuticals, Inc. Moleculas activas para el receptor de calcio.
IL105587A0 (en) * 1992-05-08 1993-09-22 Lilly Co Eli Human metabotropic glutamate receptor and related dna compounds
WO1993023569A1 (en) * 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US6228610B1 (en) * 1993-09-20 2001-05-08 Novartis Corporation Human metabotropic glutamate receptor subtypes (hmR4, hmR6, hmR7) and related DNA compounds
US6274330B1 (en) * 1993-12-30 2001-08-14 Zymogenetics, Inc. L-AP4 sensitive glutamate receptors
EP0759978A4 (en) * 1994-05-16 1997-12-29 Human Genome Sciences Inc CARRIER PROTEIN FOR NEW TRANSMITTERS
JPH10507934A (ja) * 1995-07-26 1998-08-04 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 代謝指向型グルタミン酸受容体に活性を示す化合物を同定するためのキメラ受容体および方法、ならびに神経学的障害および疾患の治療におけるそのような化合物の使用

Also Published As

Publication number Publication date
DE69737990T2 (de) 2008-09-11
AU3715697A (en) 1998-01-07
US6077675A (en) 2000-06-20
WO1997048724A3 (en) 1998-03-26
WO1997048724A2 (en) 1997-12-24
DE69737990D1 (de) 2007-09-20
US6051688A (en) 2000-04-18
EP0882065A2 (en) 1998-12-09
US6084084A (en) 2000-07-04
EP0882065B1 (en) 2007-08-08
JP2000506392A (ja) 2000-05-30
IL125711A (en) 2006-09-05
ATE369385T1 (de) 2007-08-15
IL125711A0 (en) 1999-04-11
ES2292193T3 (es) 2008-03-01
CA2246751A1 (en) 1997-12-24

Similar Documents

Publication Publication Date Title
US6084084A (en) Human metabotropic glutamate receptor
EP0783577B1 (en) Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
US6420532B1 (en) Method of obtaining compositions comprising Y2 specific compounds
JP4570774B2 (ja) Ｇ−タンパク質共役受容体およびそれらの使用
AU695641B2 (en) Human metabotropic glutamate receptor subtypes (HMR4, HMR6, HMR7) and related DNA compounds
EP0866860B1 (en) Novel tyrosine kinase receptors and ligands
US6534287B1 (en) Human metabotropic glutamate receptor
US6413740B1 (en) Tyrosine kinase receptors and ligands
WO1994009828A1 (en) Dna encoding a human serotonin receptor (5-ht4b) and uses thereof
WO1999051636A9 (en) Gaba b receptor
US20050186658A1 (en) Chimeric metabotropic glutamate receptors and uses thereof
US6353091B1 (en) Human N-type calcium channel isoform
AU750179B2 (en) Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
US20020156265A1 (en) DNA encoding a GABABR2 polypeptide and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)